A clinical review of the t:slim X2 insulin pump. (1st December 2020)

• Record Type: Journal Article
• Authors: Berget, Cari; Lange, Samantha; Messer, Laurel; Forlenza, Gregory P.
• Is Part Of: Expert opinion on drug delivery. Volume 17:Number 12(2020)
• Page Start: 1675
• Page End: 1687
• Publication Date: 2020-12-01
• Subjects: Type 1 diabetes -- inulin pumps -- automated insulin delivery -- hybrid closed loop -- predictive low glucose suspend; Drug delivery devices -- Periodicals; Drug delivery systems -- Periodicals; 615.605
• DOI: 10.1080/17425247.2020.1814734
• Languages: English
• ISSNs: 1742-5247

Abstract

ABSTRACT: Insulin pumps are commonly used for intensive insulin therapy to treat type 1 diabetes in adults and youth. Insulin pump technologies have advanced dramatically in the last several years to integrate with continuous glucose monitors (CGM) and incorporate control algorithms. These control algorithms automate some insulin delivery in response to the glucose information received from the CGM to reduce the occurrence of hypoglycemia and hyperglycemia and improve overall glycemic control. The t:slim X2 insulin pump system became commercially available in 2016. It is an innovative insulin pump technology that can be updated remotely by the user to install new software onto the pump device as new technologies become available. Currently, the t:slim X2 pairs with the Dexcom G6 CGM and there are two advanced software options available: Basal-IQ, which is a predictive low glucose suspend (PLGS) technology, and Control-IQ, which is a Hybrid Closed Loop (HCL) technology. This paper will describe the different types of advanced insulin pump technologies, review how the t:slim X2 insulin pump works, and summarize the clinical studies leading to FDA approval and commercialization of the Basal-IQ and Control-IQ technologies.